Naprosyne

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Naprosyne

Property Description
Active Ingredient Naproxen Sodium
Form Oral Solid Dosage (Tablets, Suspension)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use Pain relief, reduction of inflammation and fever
Origin Synthetic, Propionic Acid Derivative

What Type of Medicine is Naprosyne?

Naprosyne, whose active ingredient is Naproxen Sodium, is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This pharmacological designation establishes the drug as a powerful, general-purpose medicine used for its anti-inflammatory, analgesic, and antipyretic properties. The active molecule belongs to the propionic acid derivative group, a classification of synthetic compounds widely utilized in clinical practice. The NSAID class of drugs functions through the inhibition of cyclooxygenase enzymes, which are key mediators of the body's inflammatory response. This classification is clinically recognized for providing relief in conditions involving significant inflammation, such as managing discomfort following strenuous activity.

As a single-active-ingredient product, Naprosyne is designed to deliver the specific therapeutic effects of Naproxen Sodium. It is administered via the oral route, primarily available in oral tablets and oral suspension forms.


Composition and Available Forms of Naproxen Sodium

The core of Naprosyne’s composition is Naproxen Sodium, which is the sodium salt formulation of Naproxen. This specific chemical structure is crucial because the presence of the sodium salt significantly enhances the compound’s solubility, thereby promoting a rapid rate of absorption within the digestive system. The sodium salt formulation facilitates this faster systemic availability, leading to a quicker onset of action compared to the Naproxen base.

In addition to standard immediate-release tablets, formulations may include specialized delayed-release tablets, utilizing common pharmaceutical excipients to ensure stability and proper delivery. The focus on the sodium salt formulation is a key differentiating feature for the rapid action it facilitates, setting it apart from slower-absorbing, non-salt NSAID preparations.


General Purpose: Analgesic, Anti-Inflammatory, and Antipyretic Action

The primary function of Naprosyne is to deliver analgesic (pain-relieving), anti-inflammatory (swelling-reducing), and antipyretic (fever-reducing) effects. These three actions are achieved by its primary mechanism: the modulation of the body's inflammatory cascade. By inhibiting prostaglandin synthesis, the drug limits the production of the compounds that sensitize pain receptors and drive localized inflammation. The drug is utilized for its efficacy in managing general musculoskeletal discomfort and inflammation.

Regulatory References

  1. Naproxen Classification and Use (NIH)
  2. NSAID Mechanism of Action (NIH)

What side effects are possible with Naprosyne?

Safety and Possible Side Effects

Naprosyne, like other nonsteroidal anti-inflammatory drugs (NSAIDs), carries two primary serious safety concerns as designated by the regulatory Boxed Warning: the risk of serious cardiovascular (CV) thrombotic events and serious gastrointestinal (GI) adverse events.

Serious and Clinically Significant Risks

  • Cardiovascular Events: The risk of myocardial infarction and stroke, which can be fatal, may occur early in treatment and may increase with the duration of use. The drug is contraindicated for use in the setting of coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Events: NSAIDs increase the risk of serious GI bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur without warning symptoms, and the risk is higher with increasing dosage and in elderly patients.
  • Other Serious Risks: Clinically significant reactions include severe skin reactions (e.g., Stevens-Johnson syndrome), hepatotoxicity (severe liver reactions), renal toxicity (impaired kidney function, fluid retention), and severe anaphylactic reactions.

Common Adverse Reactions

The most commonly reported adverse reactions (occurring in approximately 1% to 10% of patients) typically involve the gastrointestinal and nervous systems. These include dyspepsia, heartburn, abdominal pain, nausea, headache, dizziness, and drowsiness.

Safety Restrictions and Monitoring

  • Contraindications: Naprosyne is contraindicated in patients with a history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Pregnancy: Use is avoided starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus.
  • Monitoring: Blood pressure should be monitored during the initiation and course of therapy. Renal function monitoring is advised for patients at risk, such as those with existing renal or hepatic impairment or heart failure.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Overdose presentations officially documented in government regulatory sources primarily involve the gastrointestinal (GI) and central nervous system (CNS). Documented manifestations can include GI signs such as nausea, vomiting, heartburn, abdominal discomfort, and epigastric pain. CNS effects listed are drowsiness, dizziness, disorientation, confusion, severe headache, and tinnitus (ringing in the ears).

Severe Outcomes and Emergency Response

Overdose carries the risk of severe systemic outcomes that can be life-threatening. These officially documented complications include acute renal failure, metabolic acidosis, significant gastrointestinal bleeding, as well as neurological events like coma and seizures. Due to the risk of these serious complications, regulatory labeling explicitly mandates that individuals seek immediate medical attention or contact a Poison Control Center right away if an overdose is suspected.

Management and Specific Constraints

Official regulatory documents confirm that no specific antidote is known for Naproxen Sodium overdose. Management is centered on symptomatic and supportive care. This may involve the hospital monitoring of vital signs and can include the administration of activated charcoal, particularly when a large overdose is ingested or the patient is symptomatic within a four-hour window. Regulatory guidance specifically notes that elderly patients are at a greater risk for serious gastrointestinal events.

Therapeutic Uses of Naprosyne

What Naprosyne Treats: Main Uses and Benefits

Naprosyne (Naproxen Sodium) is applied in addressing a range of conditions involving inflammatory or irritative processes, fever, and significant pain. It may be part of symptomatic management across multiple domains where supportive relief is needed. This medication is commonly used for conditions characterized by periods of heightened symptoms like Rheumatoid Arthritis (RA), Osteoarthritis (OA), and Ankylosing Spondylitis (AS), acute gout, tendonitis, and primary dysmenorrhea (menstrual cramps).


The medication is applied in addressing joint pain, swelling, and stiffness associated with chronic arthritis, and is applied in addressing discomfort during acute or episodic changes, such as soft tissue injuries or sudden pain escalation. It also plays a role in managing systemic fever and generalized body aches. By easing these symptoms that interfere with daily functioning, Naprosyne may assist with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened discomfort.


“The symptomatic support offered by the medication helps maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Relief for Inflammation and Acute Pain Naprosyne is relevant when supportive symptom management is appropriate for both long-term chronic symptoms and sudden, intense episodic discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official regulatory documents define specific populations who are restricted from using this medicine due to risks documented in clinical practice. The use of this drug is contraindicated for several groups:

  • Individuals with a history of hypersensitivity (allergic reactions) to naproxen, aspirin, or any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Patients who are in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Those with active gastrointestinal bleeding or peptic ulceration, or a history of recurrent ulcer/hemorrhage.
  • Patients with severe renal, hepatic, or heart failure are often contraindicated or are restricted from use.

Age and Physiological Restrictions

Pediatric use is generally not established for all indications in children under two years of age. For older adults, the lowest effective dose should be used due to an increased risk of serious gastrointestinal events and potential for impaired renal function. The drug is contraindicated in women during the third trimester of pregnancy (starting at 30 weeks gestation) due to the risk of fetal cardiac complications. Use may be restricted during the second trimester (after 20 weeks) and is generally not recommended for women who are breastfeeding or attempting to conceive.

What should I know about interactions with other medicines?

Naprosyne Interactions with other medicines and products

Co-administration with other Naproxen-containing products or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) is not generally recommended due to the cumulative risk of serious adverse events. Use with analgesic doses of Aspirin is also restricted because of an increased risk of serious gastrointestinal bleeding.

Pharmacokinetic and Exposure Alterations

Naproxen has been officially documented to reduce the renal clearance of certain co-administered drugs. This interaction leads to an increase in the plasma concentrations of medicines such as Lithium, Digoxin (a cardiac glycoside), and Methotrexate (due to reduced tubular secretion). Probenecid increases Naproxen’s own plasma levels and extends its half-life by inhibiting renal clearance.


Pharmacodynamic and Efficacy Interactions

Co-administration with Anticoagulants (like Warfarin), Anti-platelet Agents, SSRIs/SNRIs, or Oral Corticosteroids enhances the risk of serious gastrointestinal (GI) bleeding due to additive effects. Naproxen may diminish the antihypertensive effect of ACE Inhibitors and ARBs, and reduce the natriuretic effect of Diuretics.


Timing and Population Constraints

A specific timing constraint exists with Mifepristone, where Naproxen should not be used for 8 to 12 days following its administration. The risk of renal function deterioration with Antihypertensives and Diuretics is specifically heightened in the elderly, those who are volume-depleted, or those with pre-existing renal impairment.

Mechanism of Action

How Naprosyne Works

Naprosyne (Naproxen) is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its pharmacodynamic effect by targeting key enzymatic processes involved in lipid mediator synthesis pathways.


Enzyme-Mediated Regulation of Prostaglandin Synthesis

Naprosyne's primary mechanism involves the non-selective inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This modulation of enzyme activity suppresses the conversion of arachidonic acid into various prostaglandins, which are lipid mediators central to signaling inflammatory and nociceptive processes within tissues.


Modulation of Inflammatory Signal Transduction

By limiting the cellular biosynthesis of pro-inflammatory prostaglandins, the drug modifies early molecular steps that shape localized physiological outcomes. This biochemical action disrupts downstream signaling cascades and influences the activation state of specific target components.


Physiological Modification of Mediated Responses

This systemic reduction in specific prostaglandin levels modifies signaling pathways associated with heightened inflammatory and thermal responses. This action results in specific physiological adjustments that modify the intensity and duration of local pathway activity.

Dosage and Administration Information

How to Use Naprosyne (Naproxen): Official Administration Guidelines

Naprosyne (naproxen) is an orally administered medication that must be used strictly according to the established guidelines.


Dosing and Administration

Guideline Area Official Instruction
Route & Forms Approved route is oral. Available forms include immediate-release (IR) tablets, delayed-release (DR) tablets, extended-release (ER) tablets, and oral suspension.
Standard Dosing Standard adult dosing for chronic conditions is typically 250 mg to 500 mg twice daily (BID) for IR/DR tablets, or 750 mg to 1000 mg once daily for ER forms.
Frequency Doses are generally scheduled to be taken once or twice daily, depending on the formulation prescribed. The lowest effective dosage for the shortest duration should be used.

Procedural and Condition-Based Rules

Administration Timing and Handling:

  • With Food: It is recommended to take Naprosyne with food, milk, or an antacid to minimize the potential for gastrointestinal upset.
  • Tablet Integrity: Delayed-release and extended-release tablets must be swallowed whole. They should never be crushed, broken, or chewed, as this alters the drug’s release mechanism.
  • Suspension: The oral suspension must be shaken well before each use to ensure proper mixing, and the dose must be measured with an accurate dosing device.

Population-Specific Rules:

  • Pediatric Use: For children aged 2 years and older, dosing is weight-based, typically 10 mg/kg of body weight daily, administered in two divided doses.
  • Renal Impairment: The drug is generally not recommended for use in patients with moderate to severe kidney impairment (creatinine clearance <30 mL/min).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Naprosyne


Evidence for Use in Chronic Inflammatory Conditions

Research has explored the use of Naproxen Sodium was studied for conditions such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. These investigations primarily involved Randomized Controlled Trials (RCTs) examining patient-reported outcomes describing discomfort and functional limitations. Research describes patterns related to physical discomfort and stiffness, with data collected over periods up to several months. While the evidence tracks changes in symptomatic endpoints, there is limited information concerning the medication's effect on the underlying structural progression of these chronic conditions.


Evidence for Use in Acute Pain and Symptom Management

The research base includes systematic reviews and controlled single-dose trials for acute pain, postoperative discomfort, and primary dysmenorrhea. Studies applied in examining symptom intensity and duration of measured effect, with data showing patterns related to the time to onset of perceptible discomfort level changes.

Research on Acute Gout and Soft Tissue Conditions

Specific short-term RCTs and Comparative Trials lasting 7 to 14 days was studied for conditions such as acute gout (gouty arthritis) and soft tissue conditions like tendinitis and bursitis. While these trials contribute to the evidence landscape, the sample sizes were modest, and evidence quality varies due to study heterogeneity.


Research in Specific Patient Groups and Evidence Gaps

Follow-up durations for chronic conditions extended up to a year, but long-term outcomes for continuous use spanning many years are not fully established. Research was studied for specific patient groups, including pediatric populations and older adults; however, data for certain subgroups defined by comorbidities remain insufficient. Overall, the comparative evidence is lacking for certain head-to-head comparisons against other available pain relievers. The results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Key Studies & References NICE Guideline: Osteoarthritis: care and management

Frequently Asked Questions (FAQ)

Common questions about Naprosyne (FAQ)


Q: How quickly should I expect Naprosyne to start working?

Studies on the active ingredient, naproxen sodium, indicate it has a fast rate of absorption after you take it. The drug is typically documented to reach its highest concentration in the bloodstream (peak plasma levels) within 1 to 2 hours following oral administration.


Q: How long does the effect of Naprosyne usually last?

The duration of the drug’s action is related to its half-life, which is the time it takes for half the drug to be eliminated from the body. Official pharmacological studies document the plasma half-life of naproxen as typically ranging between 12 and 15 hours. The duration of action is described in medical literature as lasting up to 12 hours.


Q: Can Naprosyne be used for headaches or migraines?

Yes, regulatory documents list specific conditions the drug is intended to treat. The official indications for Naprosyne include the general management of pain and inflammation, and in certain specific formulations, it is approved for the treatment of conditions like primary dysmenorrhea and migraine headache.


Q: What is the difference in purpose between Naprosyne and Tylenol (acetaminophen)?

Naprosyne is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification means it is used to provide three main effects: pain relief (analgesic), fever reduction (antipyretic), and inflammation reduction (anti-inflammatory). Acetaminophen (Tylenol) is primarily documented as an analgesic and antipyretic but lacks significant anti-inflammatory action.


Q: Can women who are pregnant or breastfeeding use Naprosyne?

Official warnings state that use of Naprosyne is generally not recommended in pregnant women after 20 weeks gestation and is specifically contraindicated starting at 30 weeks gestation due to the risk of fetal cardiac complications. The drug does pass into breast milk, and its use is generally not recommended for women who are breastfeeding.


Q: Do you need to take Naprosyne with food?

Official guidelines recommend that the drug should be taken preferably with or after food, milk, or an antacid. This procedural guidance is intended to help minimize the potential for gastrointestinal upset that can be associated with the medication.


Q: Can Naprosyne be crushed or split?

Delayed-release and extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed. Regulatory documents warn that altering these forms compromises the intended method of drug delivery.


Q: Can Naprosyne interfere with birth control pills?

Official prescribing documents list known interactions with various classes of other medicines. However, specific interaction data between Naprosyne and hormonal birth control products is not consistently or universally documented across all official regulatory summaries.


Q: Does Naprosyne interact with common supplements like turmeric or fish oil?

The official prescribing information advises informing a healthcare provider about all concurrent medications, including supplements. Omega-3 polyunsaturated fatty acids (such as those in fish oil) are sometimes noted to potentially increase the risk of bleeding when combined with Naprosyne.


Q: Is Naprosyne the same kind of medicine as Advil or Motrin?

Naprosyne (naproxen) and Advil or Motrin (ibuprofen) are both classified in the same drug family. They are both Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which means they share the same pharmacological class and a similar mechanism of action within the body.


Q: Does Naprosyne contain aspirin?

No. The sole active ingredient in Naprosyne is Naproxen Sodium. Although both are NSAIDs, Naprosyne does not contain aspirin (acetylsalicylic acid), which is listed separately in regulatory documents as a substance that may cause cross-reactivity in certain patients.


Q: Is it normal to feel a bit dizzy after taking Naprosyne?

Dizziness is classified in official prescribing documents as a common adverse reaction, meaning it is reported to occur in approximately 1% to 10% of patients. It is an expected possibility based on safety reporting.


Q: Do I need a prescription to get Naprosyne?

The regulatory label for the specific strengths and formulations of Naprosyne is marked 'Rx Only,' which designates the product as a prescription medicine requiring a valid prescription.


Q: Why is Naprosyne sometimes prescribed over-the-counter naproxen?

Naprosyne is prescribed to deliver dosage strengths or specialized tablet forms, such as delayed-release or extended-release, that are generally not available in the non-prescription, over-the-counter versions of naproxen.


Q: Is Naprosyne classified as an opioid or narcotic?

No. Naprosyne is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). The drug is not scheduled by the Drug Enforcement Administration (DEA) and is not classified as an opioid or narcotic.


Q: What happens if I forget to take a dose of Naprosyne?

Official patient guidelines advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be continued. Taking double or extra doses is not advised.


Q: Can Naprosyne cause stomach issues, and is this common?

Yes, common adverse reactions (occurring in 1% to 10% of patients) include issues like dyspepsia, heartburn, and abdominal pain. Additionally, the medication carries a regulatory Boxed Warning regarding the risk of serious gastrointestinal adverse events, including bleeding and ulceration.


Q: What is the potential impact of taking Naprosyne on kidney function?

Regulatory warnings indicate the drug can cause renal toxicity (impaired kidney function) and may lead to dose-dependent effects on prostaglandins, which could precipitate renal failure in patients with pre-existing risk factors. Renal function monitoring is advised during therapy for at-risk patients.


Q: Are there any specific foods or drinks I should avoid while taking Naprosyne?

Official documents specifically advise against the use of alcohol while taking this medication. Alcohol is documented to increase the risk of serious gastrointestinal bleeding associated with Naprosyne use.


Q: Can taking Naprosyne affect my blood pressure?

Yes, official warnings state that NSAIDs, including Naprosyne, can lead to the onset of new high blood pressure or the worsening of existing high blood pressure. Blood pressure should be monitored closely during the initiation and course of therapy.


Q: Is Naprosyne known to cause drowsiness or affect driving?

Drowsiness and dizziness are listed as common adverse reactions. Official documents state that because the drug may cause some people to become drowsy or less alert, caution should be used when performing activities that require alertness, such as driving.


Q: What are the signs of a serious reaction to Naprosyne?

Official patient information lists signs of serious reactions that require immediate attention. These include symptoms of a heart attack or stroke (chest pain, sudden weakness, slurred speech), signs of severe skin reactions (fever, blistering, skin rash), and signs of serious gastrointestinal bleeding (bloody or black/tarry stools, coughing up blood).


Q: Is it possible to become dependent on Naprosyne?

Naprosyne is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not scheduled as a controlled substance by the Drug Enforcement Administration. Official documents do not contain warnings for physical dependence or addiction in the context of controlled pain medications.


Q: How long can a person stay on Naprosyne?

The official prescribing recommendation for this class of medicine is to use the lowest effective dosage for the shortest duration necessary to control symptoms. This is consistent with regulatory guidelines for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).


Q: What research is available on the long-term use of Naprosyne?

Research has examined use for chronic conditions over periods up to a year. However, regulatory documents state that long-term outcomes for continuous use spanning many years are not fully established. Periodic monitoring is advised for patients on long-term therapy.


Q: Can Naprosyne be taken if I am also taking a blood thinner?

Taking Naprosyne with medications classified as anticoagulants (blood thinners) is documented to enhance the risk of serious gastrointestinal bleeding due to additive effects.


Q: Is Naprosyne safe for people who have asthma?

Naprosyne is contraindicated (should not be used) in patients who have a history of asthma, hives, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).


Q: Does Naprosyne work differently for chronic pain versus acute pain?

While the underlying mechanism of action is the same, the drug is officially indicated for different conditions. Separate dosage regimens and patient management strategies are specified for the long-term management of chronic conditions (like arthritis) versus the short-term treatment of acute pain or inflammation.


Q: Does taking Naprosyne at night affect sleep?

Official prescribing documents list drowsiness as a common adverse reaction that may affect your alertness. Conversely, insomnia (difficulty sleeping) is also noted in some documents as an effect that has been reported.


Q: Is it common for people to report ringing in the ears while on Naprosyne?

Tinnitus (a medical term for ringing in the ears) is listed in the official prescribing documents as an adverse reaction that has been reported by patients using this medication.


Q: Is it safe to take Naprosyne with an antidepressant?

Official prescribing documents indicate that co-administration with certain types of antidepressants, specifically Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), enhances the risk of serious gastrointestinal bleeding.


Q: Is it possible for Naprosyne to cause fluid retention or swelling?

Yes, official prescribing documents list edema (swelling) and fluid retention as potential adverse reactions that have been reported with the use of this medication.


Q: Why is the drug name 'Naprosyne' sometimes confused with 'Naproxen'?

The name 'Naprosyne' is the brand name used to identify the product. Confusion often arises because the active ingredient within the product is naproxen (most commonly in the form of naproxen sodium), which is the generic drug name.


Q: Do official prescribing documents list any mental or mood side effects for Naprosyne?

Yes, official documents list several mental and mood-related effects in the adverse reaction profiles. These include confusion (listed as common), as well as depression and mood alterations (listed as uncommon).

How should Naprosyne be stored and disposed of?

Storage and Disposal Instructions

Naprosyne (Naproxen/Naproxen Sodium) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

Official Storage Requirements

Condition Requirement (Regulatory Standard)
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Protect from light and moisture. Avoid freezing and excessive heat.
Container Store in a well-closed, light-resistant container.
Safety Keep out of the reach of children at all times.

Disposal

Unused or expired Naprosyne should be discarded following official governmental guidelines. This typically involves using a designated drug take-back program or preparing the medication for household trash disposal by mixing it with an undesirable substance and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naprosyne found in:

A-Z Index: